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SUMMARY 
Lafora disease (LD) is a rare, fatal neurodegenerative disorder characterized by the 
accumulation of glycogen-like inclusions in the cytoplasm of cells from most tissues of 
affected patients. 100 years since the first description of these inclusions, the molecular 
bases underlying the processes involved in LD physiopathology are finally being 
elucidated. The main cause for the disease relies on the activity of two proteins, the dual 
specificity phosphatase laforin and the E3-ubiquitin ligase malin, that form a functional 
complex. Laforin is unique in humans since it is comprised of a carbohydrate binding 
module attached to a cysteine-based catalytic dual specificity phosphatase domain. 
Laforin directly dephosphorylates glycogen, but other proteinaceous substrates, if 
existent, have remained elusive. Recently, an emerging set of laforin binding partners 
apart from malin have been described, suggestive of laforin roles unrelated to its 
catalytic activity. Further investigations based on different transgenic mice models have 
shown that the laforin-malin complex is also involved in other cellular processes such as 
response to ER stress and misfolded proteins clearance by the lysosomal pathway. 
However, controversial data and some missing links still make difficult to assess 
the concrete relationship between glycogen deregulation and neuronal damage leading 
to the fatal symptoms observed in LD patients, such as myoclonic seizures and epilepsy. 
Consequently, clinical treatments are far from being achieved. In the present review, we 
focus on the knowledge of laforin biology not only as a glucan phosphatase, but also as 
an adaptor protein involved in several physiological pathways. 
INTRODUCTION 
The gene encoding the glucan phosphatase laforin is mutated in Lafora progressive 
myoclonus epilepsy (LD, OMIM 254780). LD is a fatal autosomal recessive 
neurodegenerative disorder characterized by the presence of progressive neurological 
deterioration, myoclonus and epilepsy (see [1] and [2] for review). LD initially 
manifests during adolescence with generalized tonic-clonic seizures, myoclonus, 
absences, drop attacks and visual hallucinations. As the disease proceeds, patients 
enter into a vegetative state and eventually die, usually within the first decade from 
onset of the first symptoms ([1], [3]). 
A hallmark of LD is the accumulation of insoluble glucans (i.e. carbohydrates) called 
Lafora bodies (LBs) ([4], [5]). LBs form in the cytoplasm of cells from most tissues. 
LBs, like normal glycogen, are composed of glucose residues joined by -1,4-glycosidic 
linkages with branches occurring via -1,6-glycosidic linkages (reviewed in [2]). 
However, branches in LBs occur less frequently compared to glycogen, and LBs 
contain increased amounts of phosphate. These properties are shared with amylopectin, 
the major component of plant starch, and are the reason why LBs and plant starch are 
water insoluble. LD patients exhibit increased neuronal cell death, number of seizures, 
and LB accumulations as they age; thus, it is hypothesized that the LBs trigger these 
symptoms and ultimately the death of the patient [6]. 
Mutations causing LD have been identified in two genes, EPM2A ([7], [8]) and 
EPM2B (NHLRC1) [9], and there is evidence for a third locus [10]. EPM2A encodes 
the glucan phosphatase laforin, a type of dual specificity phosphatase, and EPM2B 
encodes malin, an E3-ubiquitin ligase ([9], [11], [12]). Laforin prevents Lafora disease 
by at least two mechanisms: 1) it avoids hyperphosphorylation of glycogen by 
dephosphorylating it, likely thereby allowing proper glycogen formation, and 2) laforin 
is an adapter protein and targets proteins to be ubiquitinated by the E3 ubiquitin ligase 
activity of malin. 
Lafora disease was described over 100 years ago [4]. It took almost 90 years to identify 
the two genes mutated in LD, and 96 years to define biologically relevant substrates of 
laforin and malin. Our understanding of laforin’s multiple functions sheds insights into 
the mechanisms causing LD. These advances allow us to now postulate ideas to treat 
this devastating disease. 
EPM2A gene 
Laforin is encoded by the 130 Kb four-exon gene EPM2A on chromosome 6q24 of the 
human genome. It is ubiquitously expressed in all tissues, although brain, skeletal 
muscle, heart and liver have higher levels of expression [8]. In the brain, laforin is 
expressed predominantly in cerebellum, hippocampus, frontal cortex and olfactory bulb 
[13]. Laforin expression increases after birth, reaching a maximum during the adulthood 
[13]. 
EPM2A encodes a 331 amino acid bi-modular protein with an amino-terminal  
carbohydrate binding module (CBM, residues 1-124) and a carboxy-terminal dual 
specificity phosphatase domain (DSP, residues 157-326) (Fig. 1A). Loss-of-function 
point mutations in either domain result in LD, demonstrating the essential nature of a 
functional CBM and DSP domains.(a comprehensive metaanalysis of reported 
mutations can be found in ref. [14]). 
EPM2A alternative splicing results in two laforin isoforms that are identical from 
amino acid 1-309, but contain a divergent C-terminal domain. Isoform laforin-331 is the 
most abundant form, possesses phosphatase activity, and when overexpressed in cell 
culture localizes to the cytoplasm and ER [15]. The minor isoform laforin-317 lacks 
phosphatase activity and localizes to the cytoplasm and nucleus [15]. Interestingly, 
Ganesh and colleagues found that the isoforms form heterodimers and that the 
heterodimers also lack phosphatase activity [15]. These results suggest that laforin-317 
may modulate laforin activity by binding laforin-331, then functioning as a dominant 
negative. A recent study reported three additional isoforms of varying lengths, although 
the physiological role of these isoforms is still unclear [16]. 
Domains, biochemical properties, & phylogeny Carbohydrate binding 
module (CBM) 
CBMs are non-catalytic domains classified into sixty-four families based on 
evolutionary relationships, polypeptide folds, and substrate preferences according to the 
Carbohydrate-Active Enzymes (CAZY) database [17]. Proteins containing a CBM 
utilize the domain to bind carbohydrates and enzymatically modify the carbohydrates 
with a second domain (e.g. a hydrolase domain) [18]. The laforin CBM belongs to the 
CBM20 family [19]. CBM20 domains are 90-130 amino acids long. They are one of the 
most well characterized CBM families, and are characteristic of glucosylhydrolases and 
glucotransferases from bacteria, fungi, and plants ([18], [20], [21]). CBM20 modules 
are highly heterogeneous at the amino acid level and lack invariant residues, but contain 
moderately wellconserved aromatic residues that coordinate ligand binding. The 
CBM20 module typically consists of seven β-strands that form an open-sided distorted 
β-barrel with aromatic residues interacting with glucan chains rather than the starch 
crystalline surface as seen with other CBM families [22]. In the case of laforin, the 
CBM allows laforin to bind glycogen and LBs as well as plant amylopectin ([19], 
[23], [24]). Of note, laforin is the only human phosphatase with a CBM present in the 
same polypeptide chain as the catalytic domain ([25], [26]). 
Since no crystal structure of laforin is yet available, we generated a homology model of 
the carbohydrate binding module of laforin (residues 1-116) using the best available 
structure [Geobacillus stearothermophilus cyclodextrin glycosyltransferase (PDB: 
1CYG)] [27]. The homology model suggests that the laforin CBM folds into the 
characteristic two -sheets fold, with the N- and C-termini pointing towards opposite 
ends of the longest axis of the molecule [28]. Conserved aromatic residues involved in 
carbohydrate binding are readily observable in the laforin CBM structure: W32, W85 
and W99. In the model, these residues form a compact, rigid and surface-exposed 
hydrophobic site containing inter-ring spacing appropriate for binding to (1,4)-linked 
glucoses, as is the case for glycoamylase [28]. 
Dual specificity phosphatase domain (DSP) 
Laforin contains a carboxy-terminal dual specificity phosphatase (DSP) domain. The 
DSPs belong to the larger protein tyrosine phosphatase (PTP) superfamily of cysteine-
dependent phosphatases that encompass around 107 human genes ([25], [26]). PTPs 
utilize a conserved CX5R motif to hydrolyze phosphoester bonds [26]. The DSP family 
includes phosphatases that dephosphorylate proteinaceous and/or non-proteinaceous 
substrates ([26], [29]). Similar to other DSPs, recombinant laforin dephosphorylates the 
artificial substrates para-nitrophenylphosphate (pNPP) and 3-O-methyl fluorescein 
phosphate (OMFP) ([30], [31], [32]). As a cysteine-based enzyme, laforin requires a 
reduced environment to be active and is reversibly inactivated under oxidative 
conditions [33]. 
The endogenous substrate for laforin remained elusive for some time, with several 
laboratories searching for it by targeted approaches and unbiased screening methods. 
Since laforin contains a CBM and the hallmark of LD is aberrant glycogen, multiple 
laboratories systematically tested proteins involved in glycogen metabolism as possible 
laforin substrates. In the end, a multi-system approach revealed that laforin directly 
dephosphorylates glucans instead of proteins involved in glycogen metabolism and 
these data established laforin as a glucan phosphatase ([23], [34], [35]) (see below). 
Although the DSPs share significantly less amino acid conservation than the classical 
PTPs, they still retain the characteristic αβα PTP fold. In addition, the DSPs share many 
of the conserved elements first described for the classical PTPs. These enzymes utilize a 
cysteine residue at the base of the active site cleft within the PTP loop to perform 
nucleophilic attack of the phosphorous atom of the substrate. An aspartic acid around 30 
amino acids N-terminal of the catalytic cysteine acts as the general acid catalyst, 
enhancing catalysis. A key difference between the classical PTPs and DSPs is that the 
classical PTPs possess a deeper active site allowing access to only phospho-tyrosine, 
whereas the DSPs active site is more shallow to accommodate phospho-serine, -
threonine, and –tyrosine ([26], [29]). 
The laforin DSP domain was modeled by comparing it with that of the human DUSP22 
phosphatase (PDB: 1WRM; [36]) [27]. This in silico approach suggests that the laforin 
DSP folds into the characteristic αβα PTP fold consisting of four to five -sheets 
surrounded by -helices [37]. In this structure, the PTP loop, containing the catalytic 
cysteine residue (Cys266), and the conserved Asp residue (Asp235) point towards the 
catalytic groove. Despite these efforts, a crystal structure of laforin is needed to 
determine how phospho-glucans are bound by the CBM20 and positioned into the 
laforin DSP active site. 
 
Laforin dimerization 
Recombinant laforin purified from bacteria, laforin from cell culture, and laforin from 
tissue all form dimers ([38], [39], [40]). However, the domain(s) involved in this event, 
the mechanism(s) driving dimerization, and the biological function of dimerization are 
poorly understood. One study reported that laforin forms SDS-resistant dimers both in 
vitro and in vivo [39]. In addition, it was reported that monomeric laforin is inactive 
and that all of the phosphatase activity is from dimeric laforin [39]. However, recent 
studies have challenged this finding by demonstrating that monomeric laforin is the 
most abundant form of the phosphatase under normal reduced conditions, and that 
laforin phosphatase activity is similar for both monomer and dimer species [33]. The 
discrepancy is likely due to the oxidative conditions in the experimental methods, since 
an oxidative environment drives laforin oligomerization and abolishes laforin 
phosphatase activity. In the study performed by Liu and colleagues they used little to no 
reducing agents, and for this reason they concluded that monomeric laforin was inactive 
[39]. Cumulatively, the new data establish that monomeric and dimeric laforin possess 
similar phosphatase activity and glucan binding ability, and that dimerization is 
enhanced by increased oxidation [33]. Despite these findings, no biological role was 
identified for laforin dimers. Dimerization did not affect phosphatase activity, glucan 
binding, or binding to other known interacting partners. Thus, a role for laforin-331 
homodimers is currently unknown. 
Insights from phylogeny 
The laforin gene is conserved in all vertebrate genomes, but it is absent from genomes 
of most non-vertebrate organisms including the standard model organisms yeast, flies, 
and worms. ([2], [23], [41]) (Fig. 2). Surprisingly, laforin is conserved in the 
cephalochordate Branchiostoma floridae and in the cnidarian Nematostella 
vectensis as well as in the following five protozoans Cyanidioschyzon 
merolae, Toxoplasma gondii, Eimeria tenella, Tetrahymena thermophila, and 
Plasmodium tetraurelia ([23], [41]). Thus, laforin possesses an ancient and unique 
evolutionary lineage. Laforin conservation in these five protozoa was a surprising and 
fortuitous finding. These five organisms all undergo a type of hibernation at some point 
in their life-cycle and when they “hibernate” they form an insoluble glucan (floridean 
starch) that resembles a Lafora body. This result provided an additional link to 
insoluble glucans and thus offered an insight into the biological substrate of laforin. 
A phylogenetic study of malin was also recently performed. It indicates that malin is 
present in all vertebrate species and a cephalochordate [42]. When the species 
distribution of malin was compared with that described for laforin ([23], [41]), it was 
observed that laforin and malin do not correlate in species distribution (Fig. 2). Since 
laforin is present in the genome of more evolutionarily basal organisms than malin, 
these results suggest that laforin may perform additional functions independent of 
malin. It is possible that these functions are conserved from red algae to humans, but 
these results indicate that at least in lower eukaryotes laforin possesses malin-
independent functions, likely glucan dephosphorylation [42]. 
Biological function 
Glucan phosphatase activity 
A single experiment based on unforeseen findings in the literature revealed that laforin 
is the founding member of a unique class of phosphatases that dephosphorylate 
phospho-glucans, the glucan phosphatases [34]. In the 1960s, Yokoi, Sakai and 
colleagues purified and biochemically characterized LBs from brains of LD patients 
([6], [43]). They utilized electron-probe microanalysis, by focusing a 1 micron beam of 
electrons on a LB and they analyzed the wavelength of excited X-rays to determine 
specific elements within the LB. In a small table as part of a 33 page study, they 
reported that LBs possess 2-3 fold higher amounts of phosphate compared to glycogen, 
while other elements were equal in both samples ([6], [43]). While they were unaware 
of laforin, they did postulate that ester-linked phosphate might explain why amylolytic 
enzymes are largely unable to degrade LBs [43]). In addition, they surmised that LBs 
are biochemically more like plant amylopectin than animal glycogen. 
Work by Zeeman, Smith and colleagues and the Moorhead lab using Arabidopsis also 
provided an intriguing clue to the function of laforin. These groups identified a protein 
similar to laforin in Arabidopsis that contains both a CBM and DSP domain, but the 
domains are in the opposite orientation as laforin ([44], [45]) (Fig. 1B). In addition, the 
Zeeman and Smith labs demonstrated that mutation of the gene results in an 
accumulation of starch and designated the protein as SEX4 (Starch EXcess phenotype 
4) [45]). Prior to these data, multiple laboratories had identified glucan water dikinase 
(GWD) and phosphoglucan water dikinase (PWD) as two Arabidopsis dikinases that 
phosphorylate the C6 and C3 position of glucose moieties on starch, respectively ([46], 
[47], [48], [49]). 
These findings, along with the finding of laforin in protozoan models, provided the 
impetus to test laforin as a glucan phosphatase. Initially, laforin was shown to 
dephosphorylate amylopectin from plant starch ([23], [34]). This result prompted the 
hypothesis that laforin removes phosphate monoesters from glycogen, allowing 
glycogen metabolism to proceed normally. In the absence of this activity, glycogen 
would accumulate more phosphate residues and longer unit chains, due to inhibited 
branching by the phosphates, and eventually would form an insoluble LB that 
biochemically resembles amylopectin. The presence of phosphate groups in glycogen 
was demonstrated back in the 1980s and 1990s ([50], [51]) but up to now, no report on 
how these phosphates were removed was known. Roach and colleagues confirmed the 
in vitro dephosphorylation of amylopectin by laforin and also showed that mammalian 
glycogen was a substrate of this phosphatase [35]. In addition, they demonstrated that 
glycogen isolated from laforin knockout mice was hyperphosphorylated and developed 
an abnormal structure ([35], [52]). Cumulatively, these data established laforin as a 
glucan phosphatase and provide one mechanism for LB formation. A recent paper from 
the Roach and DePaoli-Roach labs completed the circle by identifying the source of 
glycogen phosphate. They found that glycogen synthase incorporates the β-phosphate of 
UDP-glucose (its substrate) at a rate of 1 phosphate/10,000 glucose moieties as C2- and 
C3-linked monoesters [53]. Thus, one function for laforin is to prevent the enzymatic 
error mediated by glycogen synthase leading to the phosphorylation of glycogen. 
Adapter protein of enzymes involved in glycogen synthesis 
Malin is an E3-ubiquitin ligase that contains an amino-terminal RING domain and six 
carboxyterminal NHL domains that are predicted to form a β-propeller type protein 
interaction domain ([11], [12]) (Fig. 1C). Multiple labs have demonstrated that laforin 
and malin form a complex and that laforin recruits substrates to be ubiquitinated by 
malin. These substrates are ubiquitinated by malin in a laforin-dependent manner and 
many of the substrates are enzymes involved in glycogen synthesis. The laforin-malin 
complex binds and ubiquitinates the muscle isoform of glycogen synthase [54] and 
PTG, the glycogen targeting subunit of protein phosphatase type 1 (PP1) ([55], [56]). In 
these experiments, the laforin-malin complex ubiquitinates the substrate, decreases the 
substrate protein levels, and downregulates glycogen levels (Fig. 3). The role of laforin 
as an adapter protein is uncoupled from its role as a glucan phosphatase since a 
catalytically inactive phosphatase mutant (C266S) still recruits malin and targets it to 
glycogen related enzymes ([55], [56]). In addition to PTG and glycogen synthase, one 
report suggests that malin ubiquitinates glycogen debranching enzyme (GDE/AGL) 
[57]. 
This report shows that AGL ubiquitination is increased in a wild-type malin-dependent 
manner when both proteins are overexpressed. Additionally, these investigators 
demonstrated that increased levels of cAMP increases the interaction between malin and 
AGL as measured by co-immunoprecipitation and subcellular localization. New 
information on the contribution of the laforin-malin complex to glycogen regulation has 
been reported very recently. Jana and colleagues reported that the laforin-malin complex 
interacts with neuronatin, an 81 amino acid protein that stimulates glycogenesis. The 
laforin-malin complex ubiquitinates and promotes the proteasomal degradation of 
neuronatin; therefore, they proposed that in the presence of an inactive laforin-malin 
complex, neuronatin accumulates and hyperstimulates glycogen synthesis [58]. 
Many of the conclusions regarding glycogen synthase, PTG and other glycogen related 
proteins were based on cell culture experiments overexpressing malin, laforin and/or the 
putative substrate. However, multiple laboratories have recently tested these initial 
findings under more biologically relevant conditions and they have found conflicting 
results. In contrast with the cell culture data, 3- month old mice lacking laforin did not 
show increased levels of glycogen synthase or PTG in muscle or brain extracts [52]. 
Additionally, two groups found no increase in glycogen synthase, PTG or AGL 
in malin-deficient mice of 3 to 6 months of age ([59], [60]). However, a third group 
found dramatically higher levels of glycogen synthase in brain extracts from 11-month 
old malin-deficient mice compared to wild-type mice [61]. 
Although protein ubiquitination was first described as a mechanism for targeting 
proteins for rapid proteasomal degradation, in recent years other functions of 
ubiquitination have been delineated that are driven by different types of ubiquitination, 
e.g. monoubiquitination, multi- versus polyubiquitination, and different chain topology 
([62], [63]). A recent study reported that the laforinmalin complex produces K63-linked 
poly-ubiquitin chains in PTG, AMPKα and AMPKβ [64]. These results suggest that the 
modification introduced by the laforin-malin complex may play a different role from 
targeting substrates for degradation by the proteasome. 
It is possible that under certain circumstances the laforin-malin complex could also 
promote the formation of K48-linked ubiquitins. This possibility has also been 
described for parkin, an E3- ubiquitin ligase involved in Parkinson disease that modifies 
synphilin-1 with both K63- and K48- linked ubiquitin chains [65]. Perhaps this is the 
reason why the overexpression of laforin and malin promote the proteasomal 
degradation of PTG [55]. This possibility would reconcile the results obtained in mouse 
models lacking either laforin or malin, where it has been described that, in spite of 
having increased levels of glycogen in different tissues (skeletal muscle and brain), 
there are no differences in either the activity or the protein levels of glycogen synthase 
or PTG ([35], [59], [60]). 
Although, the most recent report on this matter indicates that in the brain of 11 month 
old mice lacking malin, there is an increase in the levels of the muscle glycogen 
synthase [61]. These results indicate that the age of the mice may prove important, as 
the previous studies examined younger mice. These latest results suggest that the 
laforin-malin complex indeed has a role in vivo in downregulating proteins involved in 
glycogen homeostasis, but more work is needed to define the mechanism of these 
events. Supporting the possible role of the laforin-malin complex in the regulation of 
PTG levels, we found that PTG protein levels were also increased in primary fibroblasts 
from LD patients [66]. Further bolstering PTG as a bona fide substrate is the ability to 
recapitulate in vitro ubiquitination of PTG by malin in a laforin-dependent manner 
using purified components [56]. 
Adapter protein in ER-stress and protein clearance 
The laforin-malin complex also plays a role in protecting cells from ER-stress 
conditions. In cell culture models depleted of laforin there is enhanced sensitivity to 
agents that trigger ER-stress, e.g. thapsigargin and tunicamicin [67]. In laforin-depleted 
cells, there is a decrease in proteasome activity and an increase in apoptosis upon drug 
treatment, as compared to control cells [67]. Similar results regarding protein 
aggregation induced cell death in malin-depleted cells were also reported [68]. 
Therefore in the absence of either laforin or malin, there is increased ER-stress response 
that eventually leads to decreased proteasome function and increased apoptosis, which 
could be important factors in the development of LD. Strong corroborating evidence for 
these cell models is that tissue from mice lacking laforin and human LD patients have 
increased ER stress markers [67] (Fig. 3). 
In addition to loss of laforin resulting in enhanced sensitivity to ER stress, laforin itself 
seems to contribute to ER stress. Overexpressed laforin is prone to aggregate and these 
aggregates localize in perinuclear aggresome structures that co-localize with ubiquitin, 
ER-chaperones, and proteasome subunits [69]. We have also observed co-localization of 
the autophagy maker p62 with these structures, which suggests that they might be 
labeled for degradation by autophagy (unpublished results). Laforin aggregation is 
enhanced when some LD mutant forms of laforin are overexpressed and these 
aggregates also contribute to increased ER-stress response and increased apoptosis [70]. 
The laforin-malin complex has also been implicated in suppressing cytotoxicity 
produced by the accumulation of misfolded proteins. Ganesh and coworkers 
overexpressed aggregate prone proteins and demonstrated that laforin-malin in 
conjunction with HSP70 degrade the aggregates and protect against cytotoxicity [71]. 
The laforin-malin complex interacts with misfolded proteins and targets them 
for degradation by the proteasome. Follow up studies demonstrated that laforin and 
malin coimmunoprecipitate with the co-chaperone protein CHIP and showed that CHIP 
stabilizes malin’s tertiary structure ([72], [73]). 
Finally, laforin has also been described as a positive regulator of autophagy. In both 
cellular and mouse models lacking laforin there is decreased autophagy. This decrease 
is due to impaired formation of autophagosomes that leads to decreased content of 
autophagic vesicles and lower levels of the LC3-II autophagic marker. The molecular 
basis of this defect is not known, although it seems that in cells lacking laforin the 
mTOR pathway is overactivated. The changes in autophagy mediated by the absence of 
laforin may lead to the accumulation of diverse autophagy substrates that would 
contribute to cell stress and may contribute to cell death [74] (Fig. 3). Similar defects in 
autophagy have been recently described in a mouse model lacking malin (Epm2b-/-) 
[75]. Therefore, autophagy dysfunction is observed in both mouse models of Lafora 
disease (Epm2a-/- and Emp2b-/-). 
Unexpected role: laforin as a tumor suppressor 
An unexpected proposed function of laforin is as tumor suppressor. One line of mice 
expressing SV40 large T antigen and a rearranged T-cell receptor (TCR) developed T 
cell lymphoma with almost 100% penetrance ([76], [77]). The Zheng laboratory later 
discovered that in these mice, the TCR disrupted exon 1 of one EPM2A locus and the 
second locus underwent epigenetic silencing and concluded that laforin could act as a 
tumor suppressor [77]. The tumor suppression is associated with laforin phosphatase 
activity, since mice injected with a T lymphoma cell line transduced with a wild type 
laforin lentiviral vector displayed protection against tumor formation, whereas mice 
injected with a T-lymphoma cell line transduced with a catalytically inactive laforin 
(C266S) were not protected [77]. The authors proposed that laforin dephosphorylated p-
Ser9-GSK3β and in the absence of laforin GSK3β would accumulate in its inactive 
phosphorylated form. As GSK3β is a key regulator of the Wnt signaling, the 
inactivation of GSK3β would lead to the accumulation of β-catenin inside the nucleus, 
producing an increase in tumorigenesis [77]. In a follow-up study, the authors reported 
that laforin negatively regulates the cell cycle through dephosphorylation of GSK3β and 
its regulation of cyclin D1. Lack of laforin results in increased levels of cyclin D1, 
which promotes cell cycle progression [78] (Fig. 3). Despite convincing data 
demonstrating that laforin suppresses tumor growth in immunocompromised mice, 
which strongly links laforin with cell cycle progression, the data that supports laforin as 
a direct GSK3β phosphatase is controversial. Other laboratories tested GSK3β as a 
laforin substrate using in vivo and in vitro methods during targeted searches for a 
substrate, before the glucan phosphatase activity was discovered, and did not observe 
dephosphorylation of GSK3β by laforin ([34], [35], [79]). Thus, the link between laforin 
and tumor suppression in immunocompromised mice remains to be elucidated. 
Et alii 
Although laforin has been definitively shown to be a glucan phosphatase, multiple 
studies have also found that laforin directly and/or indirectly interacts with many 
proteins. Multiple techniques have been utilized to identify possible interaction partners 
and/or putative substrates and these results are summarized in Table I. Many of these 
interactions have been discussed above, but, apart from malin, it is unclear at this time 
what the physiological relevance of some of these interactions may be. 
Controlling/Regulating laforin 
While the list of interactive proteins and putative roles of laforin continues to expand, to 
date only four mechanisms have been described on the regulation of laforin. The first 
discovery of how laforin is regulated was both surprising and perplexing. Using cell 
culture models we found that malin binds, ubiquitinates, and targets laforin for 
degradation; and we were able to recapitulate the ubiquitination using purified 
components in vitro [12]. This result is surprising given that laforin and malin activity 
are both necessary to inhibit Lafora body formation and LD. However, malin-directed 
degradation of laforin has been verified in multiple cell culture systems, mouse models, 
and data from LD patient tissue ([54], [55], [59], [60], [61], [67]). 
An additional mechanism regulating laforin protein levels is directly tied to glycogen 
stores.  Roach and coworkers examined mouse models that accumulate higher or lower 
levels of glycogen and found that laforin protein levels directly correlate with the 
amount of glycogen [80]. While this link has been described, a mechanism regulating 
this fluctuation is currently unknown.  
Recently, we demonstrated that laforin physically interacts with the AMPKα and 
AMPKβ subunits of the heterotrimeric AMP-activated protein kinase (AMPK), a key 
cellular energy sensor [55]. We found that AMPK is a positive regulator of the laforin-
malin complex, since the interaction between laforin and malin is enhanced under 
conditions of AMPK activation [55]. In a follow-up study, we demonstrated that AMPK 
phosphorylates laforin at Ser25 both in vivo and in vitro [27]. We found that Ser25 is 
critical for both laforin phosphatase activity and for its ability to interact with  
established binding partners, e.g. dimerization with itself, malin, and PTG [27]. These 
results suggest that laforin-Ser25 phosphorylation by AMPK modulates the laforin-
malin interaction and provides a means to regulate their role in glycogen metabolism. 
However, these data, as with many in the laforin field, are also controversial. Roach and 
colleagues investigated the levels of PTG in exercised mice, which activate AMPK, and 
they saw no change in PTG levels [59]. Thus, additional work must be done to 
determine the role of AMPK in controlling the laforin-malin complex. 
The last reported means of regulating laforin activity is via heterodimerization of 
different splice variants. Ganesh and colleagues characterized different laforin isoforms 
and found that they display distinct subcellular localization in cell culture ([15], [16]). 
In addition, they reported that heterodimerization between truncated isoforms and full-
length laforin results in a phosphatase inactive complex [15], thus offering a mechanism 
to regulate laforin function. 
LD causes & possible therapeutics 
Given the ever-expanding reports of putative laforin functions and laforin-interacting 
proteins, it is clear that multiple mechanisms drive the progression of Lafora disease. 
The different lines of data strongly suggest that glycogen phosphorylation, interactions 
with glycogen metabolism enzymes, and cellular stresses are all intimately involved in 
disease progression. However, deciphering the intercalated pathways driving these 
mechanisms will likely take many more years. 
One definitive function of laforin is to remove phosphate from glycogen. Failure to 
remove covalently attached phosphate from glycogen disrupts glycogen organization 
and results in LB formation. Laforin clearly functions as a glucan phosphatase, but all 
of the other proposed functions include some level of controversy. It seems likely that 
laforin participates in other aspects of glycogen metabolism via functioning as an 
adapter protein for malin-directed ubiquitination of some glycogen metabolism 
enzymes. If both of these functions are correct then LB formation would result from 
either lack of laforin glucan phosphatase activity or lack of laforin’s scaffolding ability, 
with either resulting in LB formation. Once a LB begins to nucleate, it seems probable 
that the cell would sense a disturbance in its homeostasis and respond with increased 
unfolded protein response (UPR), ubiquitination, and autophagy (Fig. 3). Since the 
reoccurring theme in LD is glycogen, it is not surprising that a link between laforin, 
energy metabolism, and cell cycle progression has been uncovered. How these 
pathways impact Lafora disease remains to be determined. Despite a lack of 
consensus regarding many of the proposed pathways that laforin impacts and the 
proposed laforininteracting proteins, laforin and LD researchers have made significant 
strides. These results are allowing researchers to propose and test putative therapeutic 
paths. 
Both the glucan phosphatase activity of laforin and the ability of laforin to act as a 
scaffold impinge on glycogen metabolism. In addition, if either of these functions 
falters then one would predict that inhibiting glycogen synthesis might prevent LB 
formation and if LBs are the causative agent of LD then preventing glycogen synthesis 
should relieve neuronal cell death and epilepsy. An elegant collaborative study found 
that depletion of PTG in mice lacking laforin resulted in a downregulation of glycogen 
synthesis with near-complete disappearance of Lafora bodies as well as decreased 
neuronal cell death and myoclonic epilepsy [81], supporting a role for glycogen 
dysregulation in LD pathogenesis. Thus, removing PTG, an activator of glycogen 
synthase and inhibitor of glycogen phosphorylase, dramatically reduced the hallmark 
features of LD and caused no obvious harm to the mice. This study opens the possibility 
of utilizing chemical inhibitors to disrupt the PTG-glycogen synthase interaction and/or 
the PTG-glycogen phosphorylase interaction as a means to inhibit glycogen 
accumulation and disease progression. 
A similar line of thinking could be utilized to explore therapeutic options focused on the 
UPR and autophagy. Since autophagy is impaired in the absence of laforin, the use of 
different strategies aimed to enhance autophagy could be an interesting therapeutic 
possibility. Similarly, one could attempt to enhance protein folding through the 
upregulation of chaperone proteins and/or increase proteasomal activity as a means to 
turnover misfolded proteins. 
Additional experimental therapeutics are still in their infancy. The use of gene therapy 
to express the EPM2A gene or treatment with Trojan horse liposomes (also called 
PEGylated immunoposomes) containing the gene of interest are both putative options 
[82]. In the cases where the disease is produced by nonsense mutations in the EPM2A 
gene (i.e, R241X, the most frequent mutation in Mediterranean countries), treatment 
with gentamycin or other aminoglycoside antibiotics that produce read-through of stop 
codons, could be potentially relevant. The use of these antibiotics would be clinically 
justified for compassionate use of this fatal disorder similar to its use of cystic 
fibrosis patients ([1], [83], [84]) 
In summary, 100 years after the first clinical description of LD, the molecular bases of 
the disease are beginning to be understood. However, more work is still needed to fully 
decipher the functions of the two main players in the disease, laforin and malin. With 
this knowledge, rational therapeutic designs will be proposed that could offer a window 
of hope to patients suffering from this devastating disease. 
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Table I: Laforin interaction partners. Proteins reported to interact with laforin were 
indicated, along with their biological function and the corresponding identification 





PROTEIN  FUNCTION  IDENTIFICATION 
METHOD 
REFERENCE  
Malin  E3-ubiquitin ligase  Yeast two-hybrid screening  [38]  
PTG  PPP1R3C Regulatory subunit  
Yeast two-hybrid 
screening  [38]  
GL  PPP1R3B Regulatory subunit  Co-IP  [34]  
R6  PPP1R3D Regulatory subunit  Functional interaction  [56]  
HIRIP5  Possibly involved in iron homeostasis  
Yeast two-hybrid 
screening  [85]  
EPM2AIP1  Unknown  Yeast two-hybrid screening  [86]  
GS  Glycogen synthase  Co-IP  [34]  
GSK3β  Involved in Wnt pathway regulation  
Mammalian two-
hybrid; Co-IP  [11]  
AMPKα/β 
subunits  Cell energy sensor  Yeast two-hybrid Co-IP [55]  
TAU  Microtubule-associated protein  Pull-down  [87]  
    
FIGURE LEGENDS  
 
Fig. 1: Schematic depicting of the domains present in human laforin (A), Arabidopsis 
SEX4 (B) and human malin (C). CBM, carbohydrate binding module; DSP, dual 
specificity phosphatase domain; cTP, chloroplast targeting peptide; RING, zinc-finger 
domain involved in E3-ubiquitin ligase activity; NHL, domains involved in protein-
protein interaction. 
 
Fig. 2: Laforin and malin phylogeny. Schematic view of the presence of laforin (yellow 
background) or laforin and malin (red background) in the different kingdoms of the 
eukaryotic tree of life. Groups that do not contain either laforin or malin orthologs are 
displayed on a white background. In groups containing laforin, malin or both of them, 
the corresponding organisms are indicated, as well as the type of polyglucosan used as 
energy source. Note that malin orthologs are only present in organisms that also contain 
laforin. Modified from [88]. 
 
Fig. 3: Laforin functions. Schematic view of the different functions of laforin in cell 
physiology. GS, glycogen synthase; AGL, glycogen debranching enzyme; PTG, protein 
targeting to glycogen; U, ubiquitin; P, phosphate. See text for details. Figure was 
produced using Server Medical Art platform. 
